Attenuation of Cardiac Effects of Arteriovenous Fistula Creation With Losartan

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
The primary objective is to determine if the use of losartan, an angiotensin II receptor blocker, can attenuate left ventricular hypertrophy, independent of its antihypertensive effects, in patients with near end stage chronic kidney disease (CKD) who have an arteriovenous fistula created. Secondary outcomes include the impact of the medication on BNP and hyperkalaemia
Epistemonikos ID: a45d90ec2e380cdea886d60e1792a3769627cc14
First added on: May 04, 2024